Annual industry ranking and forecast
Medtech is seeing disruptive innovation in several areas, ranging from early cancer detection to mental health. The COVID-19 pandemic is uniquely spurring the sector to innovate more broadly.
The end of the traditional EU holiday period is nearing, and the pace of regulatory activity is expected to pick up sharply as September gets underway. What can medtech expect for the rest of 2020 and into the first half of 2021, in these unprecedented times?
The emergence of multi-cancer blood tests for early detection is captivating investors and driving multi-billion-dollar acquisitions. Companies such as GRAIL, Thrive Earlier Detection and Guardant are predicting revolutionary change in the way cancer is diagnosed and treated. The biggest hurdle, however, may be coaxing health care systems and health insurers to join the revolution.
Real-time decision support came of age in dramatic style during COVID-19. GE Healthcare’s CEO of Clinical Command Centers Jeff Terry explains that AI- and app-based health system collaboration and virtualized care will become increasingly embedded as health care delivery transforms.
With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. In Vivo explores transcranial magnetic stimulation systems that are being used to treat severe anxiety and depression, among other indications. As well as the skyrocketing use of telehealth, apps and light therapy for mental health indications.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.